

CML can occur in adults (usually middle-aged) and children. The disease affects 1 to 2 people per 100,000 and accounts for 7 - 20% cases of leukemia. It is usually associated with a chromosome abnormality called the Philadelphia chromosome.
CML causes rapid growth of the blood-forming cells (myeloid precursors) in the bone marrow, peripheral blood, and body tissues.
Exposure to ionizing radiation is one possible trigger for this chromosome abnormality. Such exposure could occur from a nuclear disaster or from treatment of a previous cancer, like thyroid cancer or Hodgkin's lymphoma. However, the vast majority of people treated for cancer with radiation do not go on to develop leukemia. It takes many years to develop leukemia from this cause.
Chronic myelogenous leukemia is grouped into several phases.
The chronic phase that can last for months or years. The disease may have few or no symptoms during this time. Most people are diagnosed by during this stage, when they are being tested for something else.
The accelerated phase is a more dangerous phase, during which the leukemia cells grow more quickly. Acceleration of the disease may be associated with fever (without infection), bone pain, and a swollen spleen.
If untreated, CML progresses to the blast crisis phase. This phase is very difficult to treat and is marked by a very high count of immature white blood cells (leukemia cells). Bleeding and infection may occur due to bone marrow failure.
Other possible symptoms include:
A physical examination often reveals an enlarged spleen. A CBC shows an increased number of white blood cells.
Other tests that may be done include:
This disease may also alter the results of the following tests:
Imatinib (Gleevec) is the first line of therapy for all patients. Gleevec blocks the Philadelphia chromosome and is assosicated with very high rates of remission. Similar drugs are being developed.
Sometimes a chemotherapy medicine called hydroxyurea (Hydrea) is used temporarily to control the white blood cell count.
The only known cure for CMS is a bone marrow transplant or stem cell transplantation.
You should discuss your options in detail with your oncologist.
Since the introduction of Gleevec, the outlook for patients with CMS has improved dramatically. Many patients can remain in remission for many years while on this drug.
Transplantation should be considered in all patients. Long-term cure after transplantation ranges from 60 - 80%.
Blast crisis can lead to complications of CML, including infection, bleeding, fatigue, unexplained fever, and kidney problems. Chemotherapy can have serious side effects, depending on the drugs used.
Call your health care provider if you have symptoms suggestive of CML or have been diagnosed with CML and develop a fever higher than 100°F, chills, sore throat, or cough.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. � 1997- 2008 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.